AA Amyloidosis: A Contemporary View

IF 5.7 2区医学 Q1 RHEUMATOLOGY Current Rheumatology Reports Pub Date : 2024-04-03 DOI:10.1007/s11926-024-01147-8

{"title":"AA Amyloidosis: A Contemporary View","authors":"","doi":"10.1007/s11926-024-01147-8","DOIUrl":null,"url":null,"abstract":"<h3>Abstract</h3> <span> <h3>Purpose of Review</h3> <p>Amyloid A (AA) amyloidosis is an organ- or life-threatening complication of chronic inflammatory disorders. Here, we review the epidemiology, causes, pathogenesis, clinical features, and diagnostic and therapeutic strategies of AA amyloidosis.</p> </span> <span> <h3>Recent Findings</h3> <p>The incidence of AA amyloidosis has declined due to better treatment of the underlying diseases. Histopathological examination is the gold standard of diagnosis, but magnetic resonance imaging can be used to detect cardiac involvement. There is yet no treatment option for the clearance of amyloid fibril deposits; therefore, the management strategy primarily aims to reduce serum amyloid A protein. Anti-inflammatory biologic agents have drastically expanded our therapeutic armamentarium. Kidney transplantation is preferred in patients with kidney failure, and the recurrence of amyloidosis in the allograft has become rare as transplant recipients have started to benefit from the new agents.</p> </span> <span> <h3>Summary</h3> <p>The management of AA amyloidosis has been considerably changed over the recent years due to the novel therapeutic options aiming to control inflammatory activity. New agents capable of clearing amyloid deposits from the tissues are still needed.</p> </span>","PeriodicalId":10761,"journal":{"name":"Current Rheumatology Reports","volume":"55 1","pages":""},"PeriodicalIF":5.7000,"publicationDate":"2024-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Rheumatology Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11926-024-01147-8","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of Review

Amyloid A (AA) amyloidosis is an organ- or life-threatening complication of chronic inflammatory disorders. Here, we review the epidemiology, causes, pathogenesis, clinical features, and diagnostic and therapeutic strategies of AA amyloidosis.

Recent Findings

The incidence of AA amyloidosis has declined due to better treatment of the underlying diseases. Histopathological examination is the gold standard of diagnosis, but magnetic resonance imaging can be used to detect cardiac involvement. There is yet no treatment option for the clearance of amyloid fibril deposits; therefore, the management strategy primarily aims to reduce serum amyloid A protein. Anti-inflammatory biologic agents have drastically expanded our therapeutic armamentarium. Kidney transplantation is preferred in patients with kidney failure, and the recurrence of amyloidosis in the allograft has become rare as transplant recipients have started to benefit from the new agents.

Summary

The management of AA amyloidosis has been considerably changed over the recent years due to the novel therapeutic options aiming to control inflammatory activity. New agents capable of clearing amyloid deposits from the tissues are still needed.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

AA 淀粉样变性：当代视角

摘要综述目的淀粉样蛋白 A（AA）淀粉样变性是慢性炎症性疾病的一种危及器官或生命的并发症。在此，我们回顾了 AA 淀粉样变性的流行病学、病因、发病机制、临床特征以及诊断和治疗策略。最新发现由于对潜在疾病的治疗有所改善，AA 淀粉样变性的发病率有所下降。组织病理学检查是诊断的金标准，但磁共振成像可用于检测心脏受累情况。目前还没有清除淀粉样纤维沉积物的治疗方案，因此，治疗策略主要是降低血清淀粉样蛋白 A。抗炎生物制剂极大地丰富了我们的治疗手段。肾衰竭患者首选肾移植，随着移植受者开始从新药中获益，淀粉样变性在异体移植中复发的情况已变得罕见。小结近年来，由于出现了旨在控制炎症活动的新疗法，AA 淀粉样变性的治疗方法发生了很大变化。但仍需要能够清除组织中淀粉样沉积物的新药。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Current Rheumatology Reports RHEUMATOLOGY-

CiteScore

11.20

自引率

0.00%

发文量

期刊介绍： This journal aims to review the most important, recently published research in the field of rheumatology. By providing clear, insightful, balanced contributions by international experts, the journal intends to serve all those involved in the care and prevention of rheumatologic conditions. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas such as the many forms of arthritis, osteoporosis and metabolic bone disease, and systemic lupus erythematosus. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also occasionally provided.